摘要
目的探讨不同病情与预后AECOPD患者NLR、IL-8水平变化与意义。方法选取重庆医科大学附属永川医院2018年6月至2020年1月收治的280例AECOPD患者(AECOPD组),另外选取同期进行体检的健康人员100例(健康组),以回顾性分析开展研究,检测两组研究对象NLR与IL-8水平。280例AECOPD患者均接受临床内科常规治疗,根据治疗后的预后情况分为生存组(266例)与死亡组(14例),按照病情严重程度分为Ⅰ级(41例)、Ⅱ级(116例)、皿级(90例)、Ⅳ级(33例),比较不同预后情况AECOPD患者的NLR与IL-8水平。结果AECOPD组患者NLR、IL-8水平均高于健康组(P<0.05);死亡组AECOPD患者的NLR、IL-8水平均高于生存组(PV0.05);随着病情严重程度升高,AECOPD患者NLR、IL-8水平均逐渐升高(P<0.05)o结论NLR与IL-8水平可作为预测AECOPD患者病情和预后的有效指标,临床应用价值较高。
Objective To explore the change and value of NLR and IL-8 levels in the different of condition and prognosis of AECOPD patients.Methods A total of 280 AECOPD patients(AECOPD group)admitted to Yongchuan Hospital of Chongqing Medical University from June 2018 to January 2020 were selected.In addition,100 healthy persons(health group)who underwent physical examinations during the same period were selected,conduct research with retrospective analysis.NLR and IL-8 levels in the two groups of subjects were detected.280 patients with AECOPD received routine clinical medical treatment.According to the prognosis after treatment,they were divided into survival group(266 cases)and death group(14 cases).According to the severity of the disease,they were divided into grade I(41 cases),grade U(116 cases),grade HI(90 cases)and grade IV(33 cases).The NLR and IL-8 levels of AECOPD patients with different prognosis were compared.Results The levels of NLR and IL-8 in the AECOPD group were higher than those in the healthy group(P<0.05);The levels of NLR and IL-8 in the AECOPD death group were higher than those in the survival group(P<0.05);As the severity of the disease increased,the levels of NLR and IL-8 in patients gradually increased(P<0.05).Conclusion The NLR and IL-8 levels can be used as an effective indicator to predict the condition and prognosis of patients with AECOPD,and has high clinical application value.
作者
姚草原
YAO Caoyuan(Department of Respiratory and Critical Care Medicine,Yongchuan Hospital of Chongqing Medical University,Chongqing 402160,china)
基金
重庆市永川区科学技术委员会自然科学基金项目(编号:Yoste,2018nb0231)。
